Pilot study of the significance of PTEN expression in patients with hormone refractory prostate cancer (HRPC) treated with Cetuximab as monotherapy for 8 weeks, followed by Docetaxel plus Cetuximab.
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2012
At a glance
- Drugs Cetuximab (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 29 Mar 2012 Actual end date (31 Mar 2011) added as reported by European Clinical Trials Database.
- 29 Mar 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.